Pharmaceuticals
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication
SHANGHAI , July 18, 2023 /PRNewswire/ -- The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma ofthe United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) ("this new ind...
2023-07-19 10:42
2300
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
SHANGHAI, July 18, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA). 9MW2921 is dev...
2023-07-19 00:00
3882
Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility
INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual report outlines the company's progress toward its sustain...
2023-07-18 19:00
2938
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
* DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics * Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients * Acquisitio...
2023-07-18 15:00
6162
SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech'
SK Biopharmaceuticals CEO Donghoon Lee maps out its medium to long-term strategy at a press conference SK Biopharmaceuticals mobilizes its cutting-edge modality platforms of radiopharmaceutical therapy (RPT), targeted protein degradation (TPD), and cell and gene therapy (CGT) aligning with its v...
2023-07-18 09:00
2501
Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
JIUQUAN, China, July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), datedJuly ...
2023-07-17 22:30
6121
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
* Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS * Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform * BIORCHESTRA to receive in-kind products and services from Merck Group CAMBRIDGE, Mas...
2023-07-17 21:28
3069
GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development
SUZHOU, China, July 17, 2023 /PRNewswire/ -- On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors...
2023-07-17 17:00
2150
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2023-07-13 18:11
5063
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
BOSTON, July 12, 2023 /PRNewswire/ -- Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr.Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. Wit...
2023-07-12 18:46
3815
Doer Biologics Announces License Agreement with BioNTech
HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE (Nasdaq...
2023-07-11 11:49
2785
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
2023-07-10 19:30
2816
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services
SUZHOU, China, July 7, 2023 /PRNewswire/ -- Crystal Pharmatech, a leading pharmaceutical technology company, has received dual recognition from its esteemed partner, Allorion Therapeutics (Boston, US / Guangzhou, China) who is an innovation-based biotech company aiming at developing novel drug mo...
2023-07-07 21:00
3735
280 Bio receives IND approval from the FDA for YL-17231
---The Company announces to initiate Phase 1 Clinical Trial with the KRAS inhibitor YL-17231 in US-- SHANGHAI and SOUTH SAN FRANCISCO, Calif. , July 7, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today annou...
2023-07-07 20:00
3703
Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs
SUZHOU, China, July 6, 2023 /PRNewswire/ -- GeneQuantum Healthcare, a leader in the innovative bioconjugation technologies for ADC new drug development, announced the expansion of its partnership with a South Korean biotech company Aimed Bio today. This strategic collaboration aims to jointly dev...
2023-07-07 10:19
2624
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment
SHANGHAI, July 6, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the completion of patient enrollment for...
2023-07-06 18:33
2649
Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China
SUZHOU, China and ROCKVILLE, Md., July 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of the Chi...
2023-07-06 10:38
2472
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment ofFurqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible fo...
2023-07-05 22:05
3014
TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist inChina - TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis inEurope by the end of the year BOSTON and SEONGNAM, South Korea, July 5, 2023 /P...
2023-07-05 20:00
3687
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the publication of a manuscript entitled "C...
2023-07-05 20:00
2617
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
8012
Sungrow Calls for Scenario-based and integrated systems to Accelerate the Next Phase of the Renewable Energy Transition
2026-09-09 22:26
6808
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
2026-09-07 13:00
6159